Cancer Progress and Priorities: Lung Cancer

Matthew B Schabath, Michele L Cote, Matthew B Schabath, Michele L Cote

Abstract

In the United States, lung cancer is the second most common diagnosed cancer and the leading cause of cancer-related death. Though tobacco smoking is the major risk factor accounting for 80 to 90% of all lung cancer diagnoses, there are numerous other risk factors that have been identified as casually associated with lung cancer etiology. However, there are few causally-linked risk factors for lung cancer diagnosed among never smokers which, if considered a unique reportable category, is the 11th most common cancer and the 7th leading cause of cancer-related death. Lung cancer survival has only marginally improved over the last several decades, but the availability of screening and early detection by low-dose computer tomography and advances in targeted treatments and immunotherapy will likely decrease mortality rates and improve patient survival outcomes in the near future.

Figures

Figure 1.
Figure 1.
Age-standardized rates (ASR) for lung cancer incidence worldwide. Figure 1a shows age-standardized incidence rates for lung cancer among males using data from GLOBOCAN, 2018. Lung cancer incidence among males is highest in Micronesia, Polynesia, Central and Eastern Europe, and Eastern Asia and lowest in most of Africa. Figure 1b shows age-standardized incidence rates for lung cancer among females using data from GLOBOCAN, 2018. Lung cancer incidence among females is highest in North America, Northern Europe, Western Europe, and Australia/New Zealand and lowest in most of Africa. Data source: GLOBOCAN 2018. Graph production: IARC (http://gco.iarc.fr/today), World Health Organization.
Figure 1.
Figure 1.
Age-standardized rates (ASR) for lung cancer incidence worldwide. Figure 1a shows age-standardized incidence rates for lung cancer among males using data from GLOBOCAN, 2018. Lung cancer incidence among males is highest in Micronesia, Polynesia, Central and Eastern Europe, and Eastern Asia and lowest in most of Africa. Figure 1b shows age-standardized incidence rates for lung cancer among females using data from GLOBOCAN, 2018. Lung cancer incidence among females is highest in North America, Northern Europe, Western Europe, and Australia/New Zealand and lowest in most of Africa. Data source: GLOBOCAN 2018. Graph production: IARC (http://gco.iarc.fr/today), World Health Organization.
Figure 2.
Figure 2.
Age-adjusted lung cancer incidence rates in the United States. Figure 2a shows age-adjusted lung cancer incidence rates for males in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Figure 2b shows age-adjusted lung cancer incidence rates for females in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Among both males and females, lung cancer incidence is higher in the Midwest and East and the highest rates are observed in the South while the lowest rates are generally found in Western states. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999-2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (www.cdc.gov/cancer/dataviz), June 2018
Figure 2.
Figure 2.
Age-adjusted lung cancer incidence rates in the United States. Figure 2a shows age-adjusted lung cancer incidence rates for males in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Figure 2b shows age-adjusted lung cancer incidence rates for females in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Among both males and females, lung cancer incidence is higher in the Midwest and East and the highest rates are observed in the South while the lowest rates are generally found in Western states. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999-2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (www.cdc.gov/cancer/dataviz), June 2018
Figure 3.
Figure 3.
Estimated age-standardized rates (ASR) for lung cancer mortality worldwide. Figure 3a shows age-standardized mortality rates for lung cancer among males using data from GLOBOCAN, 2018. Lung cancer mortality among males is highest in Eastern Europe, Western Asia, Northern Africa, and specific countries in Eastern Asia and lowest in most of Africa. Figure 3b shows age-standardized mortality rates for lung cancer among females using data from GLOBOCAN, 2018. Lung cancer mortality among females in North America, Northern Europe, Western Europe, and Australia/New Zealand and lowest in most of Africa. Data source: GLOBOCAN 2018. Graph production: IARC (http://gco.iarc.fr/today), World Health Organization.
Figure 3.
Figure 3.
Estimated age-standardized rates (ASR) for lung cancer mortality worldwide. Figure 3a shows age-standardized mortality rates for lung cancer among males using data from GLOBOCAN, 2018. Lung cancer mortality among males is highest in Eastern Europe, Western Asia, Northern Africa, and specific countries in Eastern Asia and lowest in most of Africa. Figure 3b shows age-standardized mortality rates for lung cancer among females using data from GLOBOCAN, 2018. Lung cancer mortality among females in North America, Northern Europe, Western Europe, and Australia/New Zealand and lowest in most of Africa. Data source: GLOBOCAN 2018. Graph production: IARC (http://gco.iarc.fr/today), World Health Organization.
Figure 4.
Figure 4.
Age-adjusted lung cancer mortality rates in the United States. Figure 4a shows age-adjusted lung cancer mortality rates for males in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Figure 4b shows age-adjusted lung cancer mortality rates for females in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Among both males and females, lung cancer morality is higher in the Midwest, East, and South and lowest in most Mountain states and California. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999-2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (www.cdc.gov/cancer/dataviz), June 2018.
Figure 4.
Figure 4.
Age-adjusted lung cancer mortality rates in the United States. Figure 4a shows age-adjusted lung cancer mortality rates for males in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Figure 4b shows age-adjusted lung cancer mortality rates for females in the United States, 2011 −2015, using data from U.S. Cancer Statistics Working Group. Among both males and females, lung cancer morality is higher in the Midwest, East, and South and lowest in most Mountain states and California. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2017 submission data (1999-2015): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (www.cdc.gov/cancer/dataviz), June 2018.
Figure 5.
Figure 5.
Temporal trends in 5-year relative percent survival for lung and bronchus cancer. Figure 5 shows observed and modeled trends in lung and bronchus cancer 5-year survival from 1975-2015 using data from SEER 18 (https://seer.cancer.gov/statfacts/html/lungb.html).
Figure 6.
Figure 6.
Percent of lung cancer cases at diagnosis and 5-year relative survival by stage. Figure 6 shows the percentage of lung cancer cases diagnosed in the U.S. by stage and their respective 5-year survival rates using data from SEER 18 (https://seer.cancer.gov/statfacts/html/lungb.html). “Localized” is confined to the primary sites, “regional” has spread to the regional lymph nodes, and “distant” is a cancer that has metastasized. “Unknown”, which accounts for 4% of diagnoses and has an 8.2% 5-year survival, is not shown.
Figure 7.
Figure 7.
Histological classification of lung cancer. Figure 7 shows the two major lung cancer histological categories (non-small cell lung carcinoma [NSCLC] and small-cell lung carcinoma) and the most common histological subtypes among NSCLC (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma).
Figure 8.
Figure 8.
Age-adjusted incidence rates (per 100,000) for lung and bronchus cancer by year of diagnosis and histology. Figure 8a shows age-adjusted incidence rates among females for lung and bronchus cancer by year of diagnosis and histology using SEER 9, 1973-2015. Figure 8b shows age-adjusted incidence rates among males for lung and bronchus cancer by year of diagnosis and histology using SEER 9, 1973-2015. The incidence rates are age-adjusted to the 2000 U.S. population.
Figure 8.
Figure 8.
Age-adjusted incidence rates (per 100,000) for lung and bronchus cancer by year of diagnosis and histology. Figure 8a shows age-adjusted incidence rates among females for lung and bronchus cancer by year of diagnosis and histology using SEER 9, 1973-2015. Figure 8b shows age-adjusted incidence rates among males for lung and bronchus cancer by year of diagnosis and histology using SEER 9, 1973-2015. The incidence rates are age-adjusted to the 2000 U.S. population.
Figure 9.
Figure 9.
Trends in cigarette and lung cancer death rates. Figure 9 shows the temporal trends in cigarette use versus lung cancer death rates for both males and females in the U.S. using data from the Centers for Disease Control and Prevention. Data sources from: National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention, 2017 and CDC Report on Consumption of Combustible and Smokeless Tobacco — United States, 2000-2015, page 1359.
Figure 10.
Figure 10.
Lung cancer mortality by smoking status. Figure 10 shows lung cancer mortality (per 100,000) among current smokers, former smokers, and never smokers based on published figures that were adapted from Halpern et al ([reference 148] J Natl Cancer Inst 1993; 85:457-464). Former smokers are presented by age-at-quit.

References

    1. American Cancer Society. Global Cancer Facts & Figures 4th Edition. Atlanta: American Cancer Society; 2018.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
    1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69:7–34.
    1. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014; 9:1618–1624.
    1. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2017; 12:1109–1121.
    1. Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007; 11:89–96.
    1. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31:992–1001.
    1. Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK, et al. Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. J Natl Cancer Inst 2017; 109.
    1. United States. Public Health Service. Office of the Surgeon General: The health consequences of smoking--50 years of progress : a report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2014.
    1. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer 2014; 120:2883–2892.
    1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12:175–180.
    1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389:299–311.
    1. Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget 2017; 8:57680–57692.
    1. O’Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open 2018; 8:e021611.
    1. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5:e185.
    1. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008; 9:649–656.
    1. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88:183–192.
    1. Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, et al. Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. J Natl Cancer Inst 2017; 109.
    1. Hiscock R, Bauld L, Amos A, Fidler JA, Munafo M. Socioeconomic status and smoking: a review. Ann N Y Acad Sci 2012; 1248:107–123.
    1. Hovanec J, Siemiatycki J, Conway DI, Olsson A, Stucker I, Guida F, et al. Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLoS One 2018; 13:e0192999.
    1. Fredriksen-Goldsen KI, Kim HJ, Barkan SE, Muraco A, Hoy-Ellis CP. Health disparities among lesbian, gay, and bisexual older adults: results from a population-based study. Am J Public Health 2013; 103:1802–1809.
    1. Lisy K, Peters MDJ, Schofield P, Jefford M. Experiences and unmet needs of lesbian, gay, and bisexual people with cancer care: A systematic review and meta-synthesis. Psychooncology 2018.
    1. Matthews AK, Breen E, Kittiteerasack P. Social Determinants of LGBT Cancer Health Inequities. Semin Oncol Nurs 2018; 34:12–20.
    1. Simoni JM, Smith L, Oost KM, Lehavot K, Fredriksen-Goldsen K. Disparities in Physical Health Conditions Among Lesbian and Bisexual Women: A Systematic Review of Population-Based Studies. J Homosex 2017; 64:32–44.
    1. Boehmer U, Elk R. LGBT Populations and Cancer: Is It an Ignored Epidemic? LGBT Health 2015.
    1. Quinn GP, Sanchez JA, Sutton SK, Vadaparampil ST, Nguyen GT, Green BL, et al. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. CA Cancer J Clin 2015; 65:384–400.
    1. Waterman L, Voss J. HPV, cervical cancer risks, and barriers to care for lesbian women. The Nurse practitioner 2015; 40:46–53; quiz 53-44.
    1. Graham R, Berkowitz B, Blum R, Bockting W, Bradford J, de Vries B, et al.: The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. In. Washington, DC: The National Institute of Health; 2011.
    1. Boehmer U, Miao X, Maxwell NI, Ozonoff A. Sexual minority population density and incidence of lung, colorectal and female breast cancer in California. BMJ open 2014; 4:e004461.
    1. Boehmer U, Ozonoff A, Miao X. An ecological approach to examine lung cancer disparities due to sexual orientation. Public Health 2012; 126:605–612.
    1. Gonzales G, Zinone R. Cancer diagnoses among lesbian, gay, and bisexual adults: results from the 2013-2016 National Health Interview Survey. Cancer Causes Control 2018; 29:845–854.
    1. Conron KJ, Mimiaga MJ, Landers SJ. A population-based study of sexual orientation identity and gender differences in adult health. Am J Public Health 2010; 100:1953–1960.
    1. Dilley JA, Spigner C, Boysun MJ, Dent CW, Pizacani BA. Does tobacco industry marketing excessively impact lesbian, gay and bisexual communities? Tob Control 2008; 17:385–390.
    1. Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: Department of Health, Education, and Welfare; 1964. (PHS publication no. 1103.).
    1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2016; vol. 28 . Published November 2017. Accessed June 2019.
    1. Hou W, Fu J, Ge Y, Du J, Hua S. Incidence and risk of lung cancer in HIV-infected patients. J Cancer Res Clin Oncol 2013; 139:1781–1794.
    1. Thun MJ. Early landmark studies of smoking and lung cancer. Lancet Oncol 2010; 11:1200.
    1. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368:351–364.
    1. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
    1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines; Chest 2013; 143:e1S–e29S.
    1. Peto J That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Cancer 2012; 107:406–407.
    1. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99:715–726.
    1. Markaki M, Tsamardinos I, Langhammer A, Lagani V, Hveem K, Roe OD. A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study. EBioMedicine 2018; 31:36–46.
    1. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Ostergaard JN, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila) 2012; 5:834–846.
    1. Marcus MW, Chen Y, Raji OY, Duffy SW, Field JK. LLPi: Liverpool Lung Project Risk Prediction Model for Lung Cancer Incidence. Cancer Prev Res (Phila) 2015; 8:570–575.
    1. Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 2014; 11:e1001764.
    1. National Cancer Institute, Division of Cancer Control & Population Sciences. Lung Cancer Risk Prediction Models. URL at: Accessed May 21, 2019.
    1. Lung Cancer Risk Assessment Tool. URL at: Accessed May 21, 2019
    1. Tsai J, Homa DM, Gentzke AS, Mahoney M, Sharapova SR, Sosnoff CS, et al. Exposure to Secondhand Smoke Among Nonsmokers - United States, 1988-2014. MMWR Morb Mortal Wkly Rep 2018; 67:1342–1346.
    1. Hackshaw AK. Lung cancer and passive smoking. Stat Methods Med Res 1998; 7:119–136.
    1. United States. Public Health Service. Office of the Surgeon General.: The health consequences of involuntary exposure to tobacco smoke : a report of the Surgeon General. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General; 2006.
    1. Kim AS, Ko HJ, Kwon JH, Lee JM. Exposure to Secondhand Smoke and Risk of Cancer in Never Smokers: A Meta-Analysis of Epidemiologic Studies. Int J Environ Res Public Health 2018; 15.
    1. Hori M, Tanaka H, Wakai K, Sasazuki S, Katanoda K. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Jpn J Clin Oncol 2016; 46:942–951.
    1. Villanti AC, Johnson AL, Ambrose BK, Cummings KM, Stanton CA, Rose SW, et al. Flavored Tobacco Product Use in Youth and Adults: Findings From the First Wave of the PATH Study (2013-2014). Am J Prev Med 2017; 53:139–151.
    1. Zhu SH, Sun JY, Bonnevie E, Cummins SE, Gamst A, Yin L, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tobacco Control 2014; 23:3–9.
    1. Mirbolouk M, Charkhchi P, Kianoush S, Uddin SMI, Orimoloye OA, Jaber R, et al. Prevalence and Distribution of E-Cigarette Use Among US Adults: Behavioral Risk Factor Surveillance System, 2016. Ann Intern Med 2018; 169:429–+.
    1. Jaber RM, Mirbolouk M, DeFilippis AP, Maziak W, Keith R, Payne T, et al. Electronic Cigarette Use Prevalence, Associated Factors, and Pattern by Cigarette Smoking Status in the United States From NHANES (National Health and Nutrition Examination Survey) 2013-2014. J Am Heart Assoc 2018; 7.
    1. Bao W, Xu GF, Lu JC, Snetselaar LG, Wallace RB. Changes in Electronic Cigarette Use Among Adults in the United States, 2014-2016. Jama-J Am Med Assoc 2018; 319:2039–2041.
    1. Jaber RM, Saxena A, Nasir K, Mirbolouk M, Maziak W, DeFilippis A, et al. Electronic Cigarette Use Prevalence and Pattern by Cigarette Smoking Status Among United States Adults: Findings From NHANES 2013-2014. Circulation 2017; 136.
    1. Syamlal G, Jamal A, King BA, Mazurek JM. Electronic Cigarette Use Among Working Adults - United States, 2014. Mmwr-Morbid Mortal W 2016; 65:557–561.
    1. Kosmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res 2014; 16:1319–1326.
    1. Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, Riggs NR, et al. Association of Electronic Cigarette Use With Initiation of Combustible Tobacco Product Smoking in Early Adolescence. Jama-J Am Med Assoc 2015; 314:700–707.
    1. Soneji S, Barrington-Trimis JL, Wills TA. Association Between Initial Use of e-Cigarettes and Subsequent Cigarette Smoking Among Adolescents and Young Adults: A Systematic Review and Meta-analysis (vol 171, pg 788, 2017). Jama Pediatr 2018; 172:98–98.
    1. Cai H, Wang C. Graphical review: The redox dark side of e-cigarettes; exposure to oxidants and public health concerns. Redox Biol 2017; 13:402–406.
    1. Unger M, Unger DW. E-cigarettes/electronic nicotine delivery systems: a word of caution on health and new product development. J Thorac Dis 2018; 10:S2588–S2592.
    1. Dautzenberg B, Garelik D. Patients with lung cancer: Are electronic cigarettes harmful or useful? Lung Cancer 2017; 105:42–48.
    1. Scheffler S, Dieken H, Krischenowski O, Forster C, Branscheid D, Aufderheide M. Evaluation of E-cigarette liquid vapor and mainstream cigarette smoke after direct exposure of primary human bronchial epithelial cells. Int J Environ Res Public Health 2015; 12:3915–3925.
    1. Lerner CA, Sundar IK, Yao H, Gerloff J, Ossip DJ, McIntosh S, et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One 2015; 10:e0116732.
    1. Flouris AD, Chorti MS, Poulianiti KP, Jamurtas AZ, Kostikas K, Tzatzarakis MN, et al. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhal Toxicol 2013; 25:91–101.
    1. Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest 2012; 141:1400–1406.
    1. Drummond MB, Upson D. Electronic cigarettes. Potential harms and benefits. Ann Am Thorac Soc 2014; 11:236–242.
    1. Christensen CH, Rostron B, Cosgrove C, Altekruse SF, Hartman AM, Gibson JT, et al. Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. JAMA Intern Med 2018; 178:469–476.
    1. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012; 12:385.
    1. Malhotra J, Borron C, Freedman ND, Abnet CC, van den Brandt PA, White E, et al. Association between Cigar or Pipe Smoking and Cancer Risk in Men: A Pooled Analysis of Five Cohort Studies. Cancer Prev Res (Phila) 2017; 10:704–709.
    1. Waziry R, Jawad M, Ballout RA, Al Akel M, Akl EA. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. Int J Epidemiol 2017; 46:32–43.
    1. Jett J, Stone E, Warren G, Cummings KM. Cannabis Use, Lung Cancer, and Related Issues. J Thorac Oncol 2018; 13:480–487.
    1. Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National Estimates of Marijuana Use and Related Indicators - National Survey on Drug Use and Health, United States, 2002-2014. Mmwr Surveill Summ 2016; 65:1-Cover3.
    1. National Conference of State Legislatures: Marijuna Laws. URL at webpage accessed 5/21/2019
    1. Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21:494–502.
    1. Mohite PN, Zeriouh M, Saez DG, Popov AF, Sabashnikov A, Zych B, et al. Influence of history of cannabis smoking in selected donors on the outcomes of lung transplantation. Eur J Cardiothorac Surg 2017; 51:142–147.
    1. Martinasek MP, McGrogan JB, Maysonet A. A Systematic Review of the Respiratory Effects of Inhalational Marijuana. Respir Care 2016; 61:1543–1551.
    1. Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. Int J Cancer 2015; 136:894–903.
    1. Substance Abuse and Mental Health Services Administration. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; Retrieved from .
    1. Miech RA, Johnston L, O’Malley PM, Bachman JG, Schulenberg J, Patrick ME. Trends in use of marijuana and attitudes toward marijuana among youth before and after decriminalization: the case of California 2007-2013. Int J Drug Policy 2015; 26:336–344.
    1. Miech R, Johnston L, O’Malley PM. Prevalence and Attitudes Regarding Marijuana Use Among Adolescents Over the Past Decade. Pediatrics 2017; 140.
    1. World Health Organization.: WHO handbook on indoor radon : a public health perspective. Geneva, Switzerland: World Health Organization; 2009.
    1. Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut M, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med 2005; 48:419–431.
    1. Garzillo C, Pugliese M, Loffredo F, Quarto M. Indoor radon exposure and lung cancer risk: a meta-analysis of case-control studies. Transl Cancer Res 2017; 6:S934–S943.
    1. Lubin JH, Boice JD Jr. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 1997; 89:49–57.
    1. Zhang ZL, Sun J, Dong JY, Tian HL, Xue L, Qin LQ, et al. Residential radon and lung cancer risk: an updated meta- analysis of case-control studies. Asian Pac J Cancer Prev 2012; 13:2459–2465.
    1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32:605–644.
    1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines; Chest 2013; 143:e1S–29S.
    1. Albin M, Magnani C, Krstev S, Rapiti E, Shefer I. Asbestos and cancer: An overview of current trends in Europe. Environ Health Perspect 1999; 107 Suppl 2:289–298.
    1. Huang SX, Jaurand MC, Kamp DW, Whysner J, Hei TK. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 2011; 14:179–245.
    1. Olsson AC, Vermeulen R, Schuz J, Kromhout H, Pesch B, Peters S, et al. Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. Epidemiology 2017; 28:288–299.
    1. Case BW. Asbestos, smoking, and lung cancer: interaction and attribution. Occup Environ Med 2006; 63:507–508.
    1. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 1979; 330:473–490.
    1. Reid A, de Klerk NH, Ambrosini GL, Berry G, Musk AW. The risk of lung cancer with increasing time since ceasing exposure to asbestos and quitting smoking. Occupational and Environmental Medicine 2006; 63:509–512.
    1. IARC. Agents classified by the IARC Monographs volumes 1-123. 2019. . (accessed May 9, 2019).
    1. Field RW, Withers BL. Occupational and environmental causes of lung cancer. Clin Chest Med 2012; 33:681–703.
    1. Croft JB, Wheaton AG, Liu Y, Xu F, Lu H, Matthews KA, et al. Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease - United States, 2015. MMWR Morb Mortal Wkly Rep 2018; 67:205–211.
    1. MacNee W Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:258–266; discussion 290-251.
    1. Zhang X, Jiang N, Wang L, Liu H, He R. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. Oncotarget 2017; 8:78044–78056.
    1. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011; 6:e17479.
    1. Wang H, Yang L, Zou L, Huang D, Guo Y, Pan M, et al. Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis. PLoS One 2012; 7:e46144.
    1. Brenner DR, Boffetta P, Duell EJ, Bickeboller H, Rosenberger A, McCormack V, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012; 176:573–585.
    1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469–478.
    1. Rosenberger A, Bickeboller H, McCormack V, Brenner DR, Duell EJ, Tjonneland A, et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis 2012; 33:587–597.
    1. Qu YL, Liu J, Zhang LX, Wu CM, Chu AJ, Wen BL, et al. Asthma and the risk of lung cancer: a meta-analysis. Oncotarget 2017; 8:11614–11620.
    1. Jain V, Bhardwaj A: Pneumonia, Pathology In: StatPearls. Treasure Island (FL); 2018.
    1. Mackenzie G The definition and classification of pneumonia. Pneumonia (Nathan) 2016; 8:14.
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436–444.
    1. Sogaard KK, Farkas DK, Pedersen L, Weiss NS, Thomsen RW, Sorensen HT. Pneumonia and the incidence of cancer: a Danish nationwide cohort study. J Intern Med 2015; 277:429–438.
    1. Schabath MB, Delclos GL, Martynowicz MM, Greisinger AJ, Lu C, Wu X, et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 2005; 161:412–422.
    1. Blasi F, Tarsia P, Arosio C, Fagetti L, Allegra L. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998; 4 Suppl 4:S1–S6.
    1. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005; 14:773–778.
    1. Zhan P, Suo LJ, Qian Q, Shen XK, Qiu LX, Yu LK, et al. Chlamydia pneumoniae infection and lung cancer risk: a meta-analysis. Eur J Cancer 2011; 47:742–747.
    1. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet 2016; 387:1211–1226.
    1. LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis 2017; 17:e327–e333.
    1. Keikha M, Esfahani BN. The Relationship between Tuberculosis and Lung Cancer. Adv Biomed Res 2018; 7:58.
    1. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 2017; 12:6–11.
    1. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24:506–516.
    1. Franzetti M, Ricci E, Bonfanti P. The pattern of non-AIDS-defining cancers in the HIV population: epidemiology, risk factors and prognosis. A review. Curr HIV Res 2019.
    1. Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Curr Opin HIV AIDS 2017; 12:31–38.
    1. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015; 162:335–344.
    1. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383–1388.
    1. Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017; 4:e495–e504.
    1. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer 2013; 132:1162–1169.
    1. Smith L, Brinton LA, Spitz MR, Lam TK, Park Y, Hollenbeck AR, et al. Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst 2012; 104:778–789.
    1. Wu SH, Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. Nutr Cancer 2013; 65:625–632.
    1. Wu QJ, Xie L, Zheng W, Vogtmann E, Li HL, Yang G, et al. Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a meta-analysis. Ann Oncol 2013; 24:1918–1924.
    1. Song J, Su H, Wang BL, Zhou YY, Guo LL. Fish consumption and lung cancer risk: systematic review and meta-analysis. Nutr Cancer 2014; 66:539–549.
    1. Zhu H, Zhang S. Body mass index and lung cancer risk in never smokers: a meta-analysis. BMC Cancer 2018; 18:635.
    1. Duan P, Hu C, Quan C, Yi X, Zhou W, Yuan M, et al. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci Rep 2015; 5:16938.
    1. Yang JJ, Yu D, Takata Y, Smith-Warner SA, Blot W, White E, et al. Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. J Clin Oncol 2017; 35:3055–3064.
    1. Sun Y, Li Z, Li J, Li Z, Han J. A Healthy Dietary Pattern Reduces Lung Cancer Risk: A Systematic Review and Meta-Analysis. Nutrients 2016; 8:134.
    1. Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Wiest JS, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004; 75:460–474.
    1. Bosse Y, Amos CI. A Decade of GWAS Results in Lung Cancer. Cancer Epidemiol Biomarkers Prev 2018; 27:363–379.
    1. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet 2017; 49:1126–1132.
    1. Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 2016; 17:392–406.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108.
    1. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res 2018; 7:220–233.
    1. McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal 2012; 32 Suppl 1:S69–84.
    1. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009; 15:5646–5661.
    1. National Cancer Institute. Sherlock-lung: A Genomic Epidemiologic Study of Lung Cancer in Never Smokers. URL at: Webpage accessed May 21, 2019.
    1. Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King BA, et al. Current Cigarette Smoking Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep 2018; 67:53–59.
    1. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457–464.
    1. Schabath MB. Risk models to select high risk candidates for lung cancer screening. Ann Transl Med 2018; 6:65.
    1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine 2011; 365:395–409.
    1. Schabath MB, Massion PP, Thompson ZJ, Eschrich SA, Balagurunathan Y, Goldof D, et al. Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 2016; 11:e0159880.
    1. U.S. Preventive Services Task Force. Final Update Summary: Lung Cancer: Screening. July 2015. URL at: .
    1. Centers for Medicare & Medicard Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). URL at: .
    1. Minnix JA, Karam-Hage M, Blalock JA, Cinciripini PM. The importance of incorporating smoking cessation into lung cancer screening. Transl Lung Cancer Res 2018; 7:272–280.
    1. Silva M, Pastorino U, Sverzellati N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin Radiol 2017; 72:389–400.
    1. De Koning H, Van der Aalst C, Ten Haaf K, Oudkerk M. Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. Journal of Thoracic Oncology 2018; 13:S185–S185.
    1. Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019.
    1. Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2019.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit